On November 4, 2025, just a day after Pfizer filed its suits against Novo Nordisk and Metsera, Novo Nordisk submitted an amended acquisition proposal to Metsera for $62.20 per share, a total value of $7.2 billion. Shortly after receiving the amended proposal, Metsera’s board of directors suggested to stockholders to approved Pfizer’s acquisition. 3

After [losing out to Pfizer](

Novo Nordisk navigates competition and guidance challenges with strong profitability and upcoming oral Wegovy opportunities. Learn why NVO stock is a buy.

Danish drugmaker Novo Nordisk has teamed up with Emcure Pharmaceuticals to increase access to its weight-loss drug semaglutide in India, introducing it as a second brand, Poviztra. The collaboration aims to enhance accessibility in the competitive anti-obesity market.

The Trump administration on Thursday rolled out a much-anticipated deal with drugmakers Eli Lilly and Novo Nordisk that aims to deliver lower prices for their popular GLP-1 drugs to certain Medicare and Medicaid beneficiaries and to users of TrumpRx.

Novo Nordisk A/S posted solid revenue and profit increases, with a resilient pipeline and strong dividend yield. Learn more about NVO stock here.

Trump announces deal with Eli Lilly, Novo Nordisk to lower cost of GLP-1 weight loss drugs Wegovy, Zepbound. Here's what to know and Medicare coverage

Gordon Findlay is a Novo Nordisk manager based in Switzerland who didn’t attend the White House’s Nov. 6 drug pricing announcement. Robert F. Kennedy Jr. wasn’t fleeing the scene, a White House spokesperson wrote on X; he was seeking medical attention for the man who fainted.

A drug executive collapsed in the Oval Office while President Donald Trump was announcing a deal with drugmakers to reduce prices. Here's what we know.